Literature DB >> 3927170

Antibodies against metal chelates.

D T Reardan, C F Meares, D A Goodwin, M McTigue, G S David, M R Stone, J P Leung, R M Bartholomew, J M Frincke.   

Abstract

Because monoclonal antibodies can recognize and bind to specific groups of atoms such as tumour antigens, they have promise for use in vivo as carriers of radionuclides, drugs or other appended molecules for diagnosis and treatment of disease. Attachment of metal ions to antibodies by means of bifunctional chelating agents can add the diverse nuclear, physical and chemical properties of the metallic elements to these specific binding proteins (ref. 4 and refs therein). With the ultimate aim of engineering probe-binding properties into the antibodies themselves, we have now prepared monoclonal antibodies against the EDTA chelate of indium. These antibodies show a remarkable preference for indium chelates; changing to another metal such as scandium or gallium can decrease the antibody-binding constant by more than three orders of magnitude. These antibodies also introduce a new degree of control over the biological distributions of chelated radionuclides, markedly altering their uptake in tumours and normal organs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927170     DOI: 10.1038/316265a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  48 in total

1.  Antibodies with infinite affinity.

Authors:  A J Chmura; M S Orton; C F Meares
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

Review 2.  The chemistry of irreversible capture.

Authors:  Claude F Meares
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

Review 3.  Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Authors:  Robert M Sharkey; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

4.  Monoclonal antibodies specific for mercuric ions.

Authors:  D E Wylie; D Lu; L D Carlson; R Carlson; K F Babacan; S M Schuster; F W Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 5.  Manganese and its role in Parkinson's disease: from transport to neuropathology.

Authors:  Michael Aschner; Keith M Erikson; Elena Herrero Hernández; Elena Herrero Hernández; Ronald Tjalkens
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

6.  6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Authors:  Alain Beck; Thierry Wurch; Janice M Reichert
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

7.  Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.

Authors:  Sarah M Cheal; Edward K Fung; Mitesh Patel; Hong Xu; Hong-Fen Guo; Pat B Zanzonico; Sebastien Monette; K Dane Wittrup; Nai-Kong V Cheung; Steven M Larson
Journal:  J Nucl Med       Date:  2017-07-13       Impact factor: 10.057

Review 8.  Pretargeted Imaging and Therapy.

Authors:  Mohamed Altai; Rosemery Membreno; Brendon Cook; Vladimir Tolmachev; Brian M Zeglis
Journal:  J Nucl Med       Date:  2017-07-07       Impact factor: 10.057

9.  Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.

Authors:  Rafke Schoffelen; Robert M Sharkey; David M Goldenberg; Gerben Franssen; William J McBride; Edmund A Rossi; Chien-Hsing Chang; Peter Laverman; Jonathan A Disselhorst; Annemarie Eek; Winette T A van der Graaf; Wim J G Oyen; Otto C Boerman
Journal:  Mol Cancer Ther       Date:  2010-03-30       Impact factor: 6.261

10.  Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Authors:  Sarah M Cheal; Hong Xu; Hong-Fen Guo; Sang-Gyu Lee; Blesida Punzalan; Sandhya Chalasani; Edward K Fung; Achim Jungbluth; Pat B Zanzonico; Jorge A Carrasquillo; Joseph O'Donoghue; Peter M Smith-Jones; K Dane Wittrup; Nai-Kong V Cheung; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.